eigerbioadmin

»eigerbioadmin

About eigerbioadmin

This author has not yet filled in any details.
So far eigerbioadmin has created 109 blog entries.
4 06, 2018

Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™

2018-06-04T15:46:20+00:00

Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™ PALO ALTO, Calif., June 4, 2018 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that an oral presentation [...]

Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™ 2018-06-04T15:46:20+00:00
30 05, 2018

Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference

2018-05-30T22:08:39+00:00

Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference PALO ALTO, Calif. – May 30, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on bringing to market novel product candidates for the treatment of rare diseases, announced today that David Cory, President and CEO, will present a corporate update at Jefferies 2018 Global Healthcare Conference [...]

Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference 2018-05-30T22:08:39+00:00
24 05, 2018

Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock

2018-05-24T15:10:29+00:00

Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock PALO ALTO, Calif., May 24, 2018 – Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on bringing to market novel product candidates for the treatment of rare diseases, announced today the pricing of its previously announced underwritten public offering.  The Company announced that [...]

Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock 2018-05-24T15:10:29+00:00
23 05, 2018

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock

2018-05-23T22:01:56+00:00

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock PALO ALTO, Calif., May 23, 2018 – Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on bringing to market novel product candidates for the treatment of rare diseases, announced today that it has commenced an underwritten public offering of its common stock.  Eiger intends [...]

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock 2018-05-23T22:01:56+00:00
16 05, 2018

Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF)

2018-05-16T12:06:33+00:00

Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF) Plans to Seek FDA Guidance for Potential Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) Indication PALO ALTO, Calif., May 16, 2018 – Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies [...]

Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF) 2018-05-16T12:06:33+00:00
11 05, 2018

Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results

2018-05-11T14:25:02+00:00

Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results Hepatitis Delta Virus (HDV) Program Moving into Phase 3 Phase 2 Clinical Results Planned Across All Pipeline Programs in Second Half 2018 Existing Cash Runway Extends Through Mid-2019 PALO ALTO, Calif., May 11, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of [...]

Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results 2018-05-11T14:25:02+00:00
17 04, 2018

Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to “All-Oral” Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress™ 2018

2018-04-17T15:40:32+00:00

Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to “All-Oral” Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress™ 2018 PALO ALTO, Calif., April 17, 2018 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced additional positive lonafarnib (LNF) data from the LOWR HDV (LOnafarnib With Ritonavir in Hepatitis [...]

Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to “All-Oral” Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress™ 2018 2018-04-17T15:40:32+00:00
2 04, 2018

Eiger BioPharmaceuticals to Participate in Conferences in April

2018-04-02T12:18:56+00:00

Eiger BioPharmaceuticals to Participate in Conferences in April PALO ALTO, Calif. – April 2, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that Eiger will participate at upcoming investor, scientific, and orphan drug conferences in April. C. Wainwright Global Life Science Conference at [...]

Eiger BioPharmaceuticals to Participate in Conferences in April 2018-04-02T12:18:56+00:00
26 03, 2018

Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia

2018-03-26T12:15:20+00:00

Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia PALO ALTO, Calif., March 26, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced the first patient dosed in PREVENT, a Phase 2, multi-center study of [...]

Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia 2018-03-26T12:15:20+00:00
21 03, 2018

Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program

2018-03-21T13:45:01+00:00

Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program - Phase 3 D-LIVR Trial Planned to Initiate in Second Half 2018 PALO ALTO, Calif., March 21, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today positive FDA guidance from [...]

Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program 2018-03-21T13:45:01+00:00

About Us

EigerBio Logo

We are a values-driven company that works to embody Integrity, Passion, Accountability, Creativity, and Teamwork in the pursuit of our mission.

Privacy Policy | Terms & Conditions

Therapeutic Areas

Hepatitis Delta
Post-bariatric Hypoglycemia
Lymphedema
Hutchinson-Gilford Progeria Syndrome
Home
About Eiger
Pipeline
News
Investors
Careers
Contact Us

Contact

Eiger BioPharmaceuticals, Inc.
2155 Park Boulevard
Palo Alto, CA 94306

Phone: 1-877-899-2051
Fax: 650-618-1621
Email: info@eigerbio.com

Click Here for Directions

Eiger BioPharmaceuticals © 2018 | All Rights Reserved
Toggle Sliding Bar Area